EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, aTyr Pharma's enterprise value is $24.28 Mil.
aTyr Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.35 Mil. Therefore, aTyr Pharma's EV-to-Revenue for today is 68.77.
The historical rank and industry rank for aTyr Pharma's EV-to-Revenue or its related term are showing as below:
LIFE'
s EV-to-Revenue Range Over the Past 10 Years
Min: -182.62 Med: -0.07 Max: 103.61
Current: 70.69
During the past 11 years, the highest EV-to-Revenue of aTyr Pharma was 103.61. The lowest was -182.62. And the median was -0.07.
LIFE's EV-to-Revenue is ranked worse than 81.86% of 1031
companies
in the Biotechnology industry
Industry Median: 7.91
vs LIFE: 70.69
As of today (2024-05-01), aTyr Pharma's stock price is $1.58.
aTyr Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, aTyr Pharma's PS Ratio for today is 263.33.
aTyr Pharma EV-to-Revenue Historical Data
The historical data trend for aTyr Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of aTyr Pharma's EV-to-Revenue
For the Biotechnology subindustry, aTyr Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's EV-to-Revenue falls into.
aTyr Pharma's current Enterprise Value is $24.28 Mil.
aTyr Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma's share price for today is $1.58.
aTyr Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of aTyr Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIFE has been successfully added to your 